Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children

BACKGROUND: In 2006, artemether–lumefantrine (ALU), specifically Coartem(®) (Novartis Pharma AG, Basel Switzerland), was approved as the first-line drug for treatment of uncomplicated malaria in Tanzania. Due to poor availability and affordability of the innovator’s product, the government of Tanzan...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Malar J
Päätekijät: Kilonzi, Manase, Minzi, Omary, Mutagonda, Ritah, Sasi, Philip, Kamuhabwa, Appolinary, Aklillu, Eleni
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6460845/
https://ncbi.nlm.nih.gov/pubmed/30975147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-019-2769-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia